Press Releases
Apr 24, 2008
Dako introduces unique package of RTU antibodies for cancer diagnostics
Dako’s new set of ready-to-use antibodies, Flex RTU, is the largest and most clinically relevant antibody portfolio on the market. It has been developed for diagnosis of the most common types of cancer (breast, colon, lung, prostate, melanoma, etc.).
Read MoreMar 28, 2008
Dako repositioned for growth
In 2007 Dako was acquired by EQT, a leading private equity group. The new ownership supported existing Dako programs and also implemented new initiatives, including a new workflow strategy and a number of supporting product launches. Dako strengthened several management positions and is, with a clear strategic focus, repositioned to capture future growth in the market for cancer diagnostics.
Read MoreJan 28, 2008
Dako partners with General Data to increase patient safety
Dako enters a Supply and Distribution Agreement with General Data Company Inc., becoming a global provider of a unique patient tissue sample identification and tracking system for anatomic pathology laboratories.
Read MoreJan 15, 2008
Dako receives FDA approval of TOP2A FISH pharmDx™
The US Food and Drug Administration has given Dako PMA approval to market its TOP2A FISH pharmDx™ assay. The assay is intended as an adjunct in determining the prognosis for high-risk breast-cancer patients.
Read More